Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,550.97
(
-0.84%
)
US TECH 100
23,427.20
(
-1.24%
)
Dow Jones
45,800.65
(
-0.48%
)
Brent Oil
106.31
(
1.80%
)
Bitcoin
70,066.00
(
0.24%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ghmm post# 72514

Saturday, 01/31/2009 8:16:22 PM

Saturday, January 31, 2009 8:16:22 PM

Post# of 257262

BioMS – what does Lilly have to lose to let the trial run to completion?

I’m not sure which trial you’re referring to. The MAESTRO-1 and MAESTRO-3 trials are fully enrolled, so they will run to completion, of course. The MAESTRO-2 trial is an open-label extension that LLY could curtail, but it probably would not save a material amount of money to curtail it.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today